CA3207834C - ANIMALS INCLUDING IL-4 AND IL-4R ALPHA HUMANIZED - Google Patents

ANIMALS INCLUDING IL-4 AND IL-4R ALPHA HUMANIZED

Info

Publication number
CA3207834C
CA3207834C CA3207834A CA3207834A CA3207834C CA 3207834 C CA3207834 C CA 3207834C CA 3207834 A CA3207834 A CA 3207834A CA 3207834 A CA3207834 A CA 3207834A CA 3207834 C CA3207834 C CA 3207834C
Authority
CA
Canada
Prior art keywords
human
gene
rodent
mouse
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3207834A
Other languages
English (en)
French (fr)
Other versions
CA3207834A1 (en
Inventor
Li-Hsien Wang
Yingzi XUE
Andrew J. Murphy
Sean Stevens
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Priority to CA3207834A priority Critical patent/CA3207834C/en
Publication of CA3207834A1 publication Critical patent/CA3207834A1/en
Application granted granted Critical
Publication of CA3207834C publication Critical patent/CA3207834C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA3207834A 2014-05-07 2015-05-07 ANIMALS INCLUDING IL-4 AND IL-4R ALPHA HUMANIZED Active CA3207834C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3207834A CA3207834C (en) 2014-05-07 2015-05-07 ANIMALS INCLUDING IL-4 AND IL-4R ALPHA HUMANIZED

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461989757P 2014-05-07 2014-05-07
US61/989,757 2014-05-07
CA2947307A CA2947307C (en) 2014-05-07 2015-05-07 Humanized il-4 and il-4r .alpha. animals
CA3207834A CA3207834C (en) 2014-05-07 2015-05-07 ANIMALS INCLUDING IL-4 AND IL-4R ALPHA HUMANIZED

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2947307A Division CA2947307C (en) 2014-05-07 2015-05-07 Humanized il-4 and il-4r .alpha. animals

Publications (2)

Publication Number Publication Date
CA3207834A1 CA3207834A1 (en) 2015-11-12
CA3207834C true CA3207834C (en) 2025-10-14

Family

ID=53284509

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3207834A Active CA3207834C (en) 2014-05-07 2015-05-07 ANIMALS INCLUDING IL-4 AND IL-4R ALPHA HUMANIZED
CA2947307A Active CA2947307C (en) 2014-05-07 2015-05-07 Humanized il-4 and il-4r .alpha. animals

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2947307A Active CA2947307C (en) 2014-05-07 2015-05-07 Humanized il-4 and il-4r .alpha. animals

Country Status (26)

Country Link
US (7) US9565841B2 (https=)
EP (3) EP3027015B1 (https=)
JP (5) JP6640740B2 (https=)
KR (2) KR102473565B1 (https=)
CN (2) CN110269047B (https=)
AU (3) AU2015255977B2 (https=)
BR (1) BR112016025745A2 (https=)
CA (2) CA3207834C (https=)
CY (2) CY1119773T1 (https=)
DK (2) DK3281521T3 (https=)
ES (2) ES2887852T3 (https=)
HR (2) HRP20211455T1 (https=)
HU (2) HUE038028T2 (https=)
IL (3) IL248358B2 (https=)
LT (2) LT3027015T (https=)
MX (1) MX370672B (https=)
NO (1) NO2785538T3 (https=)
PH (1) PH12016502058A1 (https=)
PL (2) PL3027015T3 (https=)
PT (2) PT3027015T (https=)
RS (2) RS62345B1 (https=)
RU (1) RU2703139C2 (https=)
SG (2) SG10201912354PA (https=)
SI (2) SI3281521T1 (https=)
SM (2) SMT201800018T1 (https=)
WO (1) WO2015171861A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2785538T3 (https=) 2014-05-07 2018-08-04
ES2783424T3 (es) 2014-06-19 2020-09-17 Regeneron Pharma Animales no humanos que tienen un gen de muerte celular programada 1 humanizado
ES2946664T3 (es) * 2014-09-17 2023-07-24 Oerlikon Surface Solutions Ag Pfaeffikon Método para producir una herramienta de corte con recubrimiento de doble capa con resistencia mejorada al desgaste
RU2020122439A (ru) 2014-11-24 2020-09-24 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3
SI3086637T1 (sl) 2014-12-05 2019-04-30 Regeneron Pharmaceuticals, Inc. Nehumane živali s humaniziranim označevalcem diferenciacije gena CD47
HUE052606T2 (hu) 2014-12-09 2021-05-28 Regeneron Pharma Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok
SG11201803409UA (en) 2015-11-20 2018-05-30 Regeneron Pharma Non-human animals having a humanized lymphocyte-activation gene 3
MX2018009513A (es) 2016-02-04 2019-01-31 Regeneron Pharma Animales no humanos que tienen un gen angptl8 modificado genéticamente.
CN109068621B (zh) 2016-02-29 2021-07-20 再生元制药公司 具有人源化的tmprss基因的啮齿类动物
TWI857389B (zh) * 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
ES3052989T3 (en) 2017-04-13 2026-01-16 Regeneron Pharma Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
MX394999B (es) 2017-09-29 2025-03-24 Regeneron Pharma Animales no humanos que comprenden un locus ttr humanizado y metodos de uso
IL310006A (en) 2017-11-30 2024-03-01 Regeneron Pharma Non-human animals containing a humanized TRKB locus
KR20250121150A (ko) 2018-03-26 2025-08-11 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
IL307286B2 (en) 2018-04-11 2026-03-01 Regeneron Pharma Methods and reagents for IL-33 quantification
JP7048051B2 (ja) 2018-07-11 2022-04-05 正徳 染井 痒みを軽減するアトピー性皮膚炎治療剤
IL278267B2 (en) * 2018-07-16 2025-02-01 Regeneron Pharma Non-human animal models of DITRA disease and their uses
CN111057721B (zh) * 2018-10-12 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化IL-4和/或IL-4Rα改造动物模型的制备方法及应用
WO2020147829A1 (zh) * 2019-01-17 2020-07-23 北京百奥赛图基因生物技术有限公司 人源化转基因动物
ES2966625T3 (es) 2019-04-04 2024-04-23 Regeneron Pharma Roedores que comprenden un locus del factor de coagulación 12 humanizado
US11891618B2 (en) 2019-06-04 2024-02-06 Regeneron Pharmaceuticals, Inc. Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
US11622547B2 (en) 2019-06-07 2023-04-11 Regeneran Pharmaceuticals, Inc. Genetically modified mouse that expresses human albumin
CN112300265B (zh) * 2019-07-29 2022-09-27 百奥赛图(北京)医药科技股份有限公司 Il33基因人源化的非人动物的构建方法和应用
US20220312749A1 (en) * 2019-08-09 2022-10-06 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric il2ra
CN112779285B (zh) * 2019-11-11 2023-01-06 百奥赛图(北京)医药科技股份有限公司 人源化il-10和il-10ra基因改造动物的构建方法和应用
US12582106B2 (en) * 2019-12-25 2026-03-24 Gempharmatech Co., Ltd. IL-15 humanized mouse model and use thereof
EP4096396A1 (en) * 2020-01-28 2022-12-07 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized pnpla3 locus and methods of use
CN111149767B (zh) * 2020-02-24 2021-07-20 中南大学湘雅二医院 一种人源化皮肤型红斑狼疮小鼠模型的构建方法和应用
CN113527485B (zh) * 2020-04-17 2024-11-15 湖南麦济生物技术股份有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
CN111808882B (zh) * 2020-09-01 2020-12-29 北京百奥赛图基因生物技术有限公司 Il7r基因人源化改造的动物模型的构建方法及其应用
CN111793646B (zh) * 2020-09-08 2021-01-15 北京百奥赛图基因生物技术有限公司 Il1r1基因人源化改造的非人动物的构建方法及其应用
CN111926039B (zh) * 2020-09-23 2021-03-16 百奥赛图(北京)医药科技股份有限公司 Il-13基因人源化的非人动物的构建方法和应用
KR20230124973A (ko) * 2020-12-21 2023-08-28 리제너론 파마슈티칼스 인코포레이티드 인간화 tslp 유전자, 인간화 tslp 수용체 유전자, 및/또는인간화 il7ra 유전자를 갖는 비인간 동물
WO2022247936A1 (en) * 2021-05-28 2022-12-01 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric cd36
WO2024067796A1 (zh) * 2022-09-28 2024-04-04 百奥赛图(北京)医药科技股份有限公司 一种il5和/或il5ra基因人源化修饰的非人动物
AU2024208789A1 (en) * 2023-01-11 2025-07-24 Regeneron Pharmaceuticals, Inc. Systems and methods for a regulatory-compliant automated assay
WO2025175099A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. A rodent copd model

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) * 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
JP2007252370A (ja) * 2006-02-22 2007-10-04 Institute Of Physical & Chemical Research Ｉｌ−４初期発現系トランスジェニック非ヒト動物およびその利用
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US20110016543A1 (en) 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
CN102725400A (zh) * 2009-06-29 2012-10-10 麻省理工学院 制造人源化的非人类哺乳动物的方法
WO2011011767A1 (en) * 2009-07-24 2011-01-27 Sigma-Aldrich Co. Method for genome editing
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
PT2485583T (pt) 2009-10-06 2016-09-22 Univ Yale Ratinhos geneticamente modificados e enxerto
MX350385B (es) * 2011-02-15 2017-09-04 Regeneron Pharma Ratones de m-csf humanizada.
DK3590332T3 (da) 2011-10-28 2022-05-23 Regeneron Pharma Genmodificerede mus, der eksprimerer kimære major histokompatibilitetskompleks (MHC) II-molekyler
WO2013063556A1 (en) 2011-10-28 2013-05-02 Regeneron Pharmaceuticals, Inc. Humanized il-6 and il-6 receptor
SI2770821T1 (en) 2011-10-28 2018-01-31 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex of mice
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
JP6306588B2 (ja) * 2012-08-21 2018-04-04 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
IN2015DN02032A (https=) 2012-09-07 2015-08-14 Univ Yale
CA2887706C (en) 2012-11-05 2022-08-02 Regeneron Pharmaceuticals Genetically modified non-human animals and methods of use thereof
KR102714111B1 (ko) 2013-02-20 2024-10-11 리제너론 파아마슈티컬스, 인크. 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
PL2958937T3 (pl) 2013-02-22 2019-01-31 Regeneron Pharmaceuticals, Inc. Myszy ekspresjonujące humanizowany główny układ zgodności tkankowej
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
CN105592695B (zh) 2013-09-23 2018-04-10 瑞泽恩制药公司 具有人源化信号调节蛋白基因的非人动物
ES2715949T3 (es) 2013-10-15 2019-06-07 Regeneron Pharma Animales con IL-15 humanizada
SG10201811701YA (en) 2013-11-19 2019-01-30 Regeneron Pharma Non-human animals having a humanized a proliferation-inducing ligand gene
CA2929846C (en) 2013-11-19 2020-09-15 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
HUE051088T2 (hu) 2014-04-08 2021-03-01 Regeneron Pharma Humanizált FC-gamma receptorokkal rendelkezõ nem humán élõlények
SG10202003996YA (en) 2014-05-05 2020-06-29 Regeneron Pharma Humanized c5 and c3 animals
NO2785538T3 (https=) * 2014-05-07 2018-08-04

Also Published As

Publication number Publication date
NZ725615A (en) 2024-05-31
RU2016143376A (ru) 2018-06-09
KR102473565B1 (ko) 2022-12-02
IL304841B2 (en) 2026-01-01
KR102517112B1 (ko) 2023-04-03
AU2021218060C1 (en) 2024-11-07
ES2887852T3 (es) 2021-12-28
EP3281521A1 (en) 2018-02-14
US9743647B2 (en) 2017-08-29
AU2024204694A1 (en) 2024-09-05
IL304841A (en) 2023-09-01
RU2019131253A (ru) 2019-12-06
RU2703139C2 (ru) 2019-10-15
AU2021218060A1 (en) 2021-09-09
PT3281521T (pt) 2021-09-16
SI3281521T1 (sl) 2021-11-30
CN110269047A (zh) 2019-09-24
HRP20211455T1 (hr) 2022-01-07
SMT202100560T1 (it) 2021-11-12
WO2015171861A1 (en) 2015-11-12
JP2021087434A (ja) 2021-06-10
ES2656529T3 (es) 2018-02-27
US11963521B2 (en) 2024-04-23
EP3906781A1 (en) 2021-11-10
JP6838131B2 (ja) 2021-03-03
RU2016143376A3 (https=) 2018-11-22
CY1124605T1 (el) 2022-07-22
EP3027015B1 (en) 2017-11-08
HUE038028T2 (hu) 2018-09-28
PH12016502058A1 (en) 2017-01-09
US20180000056A1 (en) 2018-01-04
CA3207834A1 (en) 2015-11-12
AU2021218060B2 (en) 2024-04-11
PL3027015T3 (pl) 2018-04-30
AU2015255977B2 (en) 2021-09-02
CA2947307A1 (en) 2015-11-12
SG10201912354PA (en) 2020-02-27
US10477842B2 (en) 2019-11-19
US11109578B2 (en) 2021-09-07
IL304841B1 (en) 2025-09-01
JP7755699B2 (ja) 2025-10-16
PL3281521T3 (pl) 2022-01-03
MX370672B (es) 2019-12-19
SG11201608570YA (en) 2016-11-29
US9565841B2 (en) 2017-02-14
US20200022344A1 (en) 2020-01-23
NO2785538T3 (https=) 2018-08-04
US20150320021A1 (en) 2015-11-12
RS57073B1 (sr) 2018-06-29
IL248358B (en) 2022-11-01
IL297105B1 (en) 2023-09-01
IL248358A0 (en) 2016-11-30
JP2024159985A (ja) 2024-11-08
US20230027494A1 (en) 2023-01-26
SMT201800018T1 (it) 2018-03-08
SI3027015T1 (en) 2018-02-28
CN106470545A (zh) 2017-03-01
EP3281521B1 (en) 2021-06-30
DK3281521T3 (da) 2021-09-20
PT3027015T (pt) 2018-02-09
US20210368753A1 (en) 2021-12-02
JP2022171841A (ja) 2022-11-11
JP6640740B2 (ja) 2020-02-05
MX2016014563A (es) 2017-02-23
BR112016025745A2 (pt) 2018-01-16
IL297105A (en) 2022-12-01
US20150320022A1 (en) 2015-11-12
JP7145250B2 (ja) 2022-09-30
DK3027015T3 (en) 2018-01-22
JP2020058379A (ja) 2020-04-16
LT3027015T (lt) 2018-01-25
US10588298B2 (en) 2020-03-17
HUE055860T2 (hu) 2021-12-28
AU2015255977A1 (en) 2016-11-17
EP3027015A1 (en) 2016-06-08
CA2947307C (en) 2023-09-26
CY1119773T1 (el) 2018-06-27
IL248358B2 (en) 2023-03-01
JP2017514501A (ja) 2017-06-08
RS62345B1 (sr) 2021-10-29
US12310340B2 (en) 2025-05-27
LT3281521T (lt) 2021-09-27
NZ763861A (en) 2024-05-31
KR20220165814A (ko) 2022-12-15
CN110269047B (zh) 2021-11-02
KR20160150637A (ko) 2016-12-30
US20170311580A1 (en) 2017-11-02
IL297105B2 (en) 2024-01-01
HRP20180242T1 (hr) 2018-03-09
CN106470545B (zh) 2019-08-20

Similar Documents

Publication Publication Date Title
AU2021218060B2 (en) Humanized il-4 and il-4r alpha animals
HK40053187A (en) Humanized il-4 and il-4r alpha animals
RU2788523C2 (ru) ЖИВОТНЫЕ С ГУМАНИЗИРОВАННЫМИ IL-4 И IL-4Rα
HK1245011A1 (en) Humanized il-4 and il-4r alpha animals
HK1245011B (en) Humanized il-4 and il-4r alpha animals
HK1225575B (en) Humanized il-4 and il-4r alpha animals
HK1225575A1 (en) Humanized il-4 and il-4r alpha animals

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230728

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250312

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250312

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250312

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250425

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250425

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20250709

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250723

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250723

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20251008

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20251014